Illinois House Bill 53 (Prior Session Legislation)

---

Spectrum: Partisan Bill (Democrat 5-0)
Status: Introduced on January 9 2019 - 25% progression, died in committee
Action: 2019-03-29 - House Committee Amendment No. 1 Rule 19(c) / Re-referred to Rules Committee
Pending: House Rules Committee
Text: Latest bill text (Introduced) [HTML]

Amends the Illinois Food, Drug and Cosmetic Act. Requires manufacturers of brand name or generic prescription drugs to notify State purchasers, health insurers, health care service plan providers, pharmacy benefit managers, and the General Assembly of specified increases in drug prices at least 60 days before such increase and the cost of specified new prescription drugs within 3 days after approval by the U.S. Food and Drug Administration. Provides that within 30 days after such notifications, prescription drug manufacturers shall report specified information to State purchasers, health insurers, health care service plan providers, pharmacy benefit managers, and the General Assembly. Provides that failure to report such information shall result in a specified civil penalty. Requires the General Assembly to conduct an annual public hearing on aggregate trends in prescription drug pricing. Provides that if the manufacturer of a prescription drug or its agent meets or otherwise communicates with a prescriber for the purpose of marketing a drug, then the manufacturer or its agent shall disclose to the prescriber if any ingredient in the drug it is marketing is known to pose a risk of dependency in humans. Makes other changes.

DRUG MANUFACTURER-DISCLOSURES

Rep. Mary Flowers [D]	Rep. Michael Zalewski [D]	Rep. Latoya Greenwood [D]	Rep. Rita Mayfield [D]
Rep. Elizabeth Hernandez [D]

Date	Chamber	Action
2019-03-29	House	House Committee Amendment No. 1 Rule 19(c) / Re-referred to Rules Committee
2019-03-29	House	Rule 19(a) / Re-referred to Rules Committee
2019-03-26	House	House Committee Amendment No. 1 Rules Refers to Prescription Drug Affordability & Accessibility Committee
2019-03-21	House	House Committee Amendment No. 1 Referred to Rules Committee
2019-03-21	House	House Committee Amendment No. 1 Filed with Clerk by Rep. Mary E. Flowers
2019-03-13	House	Added Co-Sponsor Rep. Elizabeth Hernandez
2019-02-27	House	Added Chief Co-Sponsor Rep. Rita Mayfield
2019-02-27	House	Added Chief Co-Sponsor Rep. LaToya Greenwood
2019-02-14	House	Added Chief Co-Sponsor Rep. Michael J. Zalewski
2019-01-29	House	Assigned to Prescription Drug Affordability & Accessibility Committee
2019-01-09	House	Referred to Rules Committee
2019-01-09	House	First Reading
2018-12-07	House	Prefiled with Clerk by Rep. Mary E. Flowers

Chapter	Article	Section	Citation Type	Statute Text
410	620	16.2	New Code	See Bill Text
410	620	16.3	New Code	See Bill Text

Type	Source
Summary	https://www.ilga.gov/legislation/BillStatus.asp?DocNum=53&GAID=15&DocTypeID=HB&SessionID=108&GA=101
Text	https://www.ilga.gov/legislation/101/HB/10100HB0053.htm
Amendment	https://www.ilga.gov/legislation/101/HB/10100HB0053ham001.htm